Skip to main content

Deadline this week for the CCTG Award for Excellence in Clinical Trials Conduct

Nominations are open until March 31, 2023!

The inaugural CCTG Award for Excellence in Clinical Trials Conduct will be presented this year at the Recognition Awards at the Annual Spring Meeting of Participants to an individual who exemplifies excellence in clinical trial operations and/or compliance at their institution. Trial operations include trial activation, ethics submission, consent and support of patients, oversight of the medicinal product, data management, and local quality management. The individual may have contributed significantly to the CCTG program and/or to specific CCTG trials within an Institution​.

Nomination Process: Submit a letter detailing the nominee’s background and achievements, involvement in the activities/trials of the Phase III Program in 2022/2023, and why he/she is a candidate for the award. Candidates may be nominated by their mentors, colleagues, or may self-nominate.

Deadline: March 31, 2023. Please submit all nominations to Heather Stanton, at hstanton@ctg.queensu.ca.

Make sure to attend the Recognition Awards on Friday April 28, 2023 - 5:30 - 6:00. Other recognition awards include:

  • Founder’s Award: Dr. Joseph Pater - Excellence in Clinical Trials Research Presented to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
  • Dr. Ralph Meyer Phase III Young Investigator Award - Presented to a young investigator who worked the at CCTG Central Office, on a Phase III trial, or contributed significantly to the conduct of a Phase III trial at a member centre.
  • Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award - Presented to a new investigator who has worked at the CCTG Central Office, IND projects, or has contributed significantly to the conduct of an IND trial at a member centre.
  • Team Awards: Phase III and Investigational New Drug Program - Presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance is determined by the Executive IND Committee and Clinical Trials Committee.